Windtree Therapeutics, Inc. · OTC:WINT
Windtree Therapeutics — Investor Presentation (April 2023)
37 slides from Windtree Therapeutics's investor presentation, Apr 3, 2023
Slide 1: Windtree Therapeutics Company Overview
Windtree Therapeutics \ Company Overview April 3, 2023 Se we WINDTREE (NASDAQ: WINT)
Slide 2: Forward-Looking Statements
Forward-Looking Statements ‘This presentation includes forward-looking statements within the meaning of Section 27Aof the Securities Actof 1933, as amended, and Section 21E ofthe Securities Exchange Act of 1934, as amended. These statements, among other things, include statements about the Company's
Slide 3: Windtree Therapeutics and Istaroxime Highlights
Windtree Therapeutics and Istaroxime Highlights v qq Biopharmaceutical company with advanced clinical focus on significant acute CV markets with high unmet needs and with supportive regulatory paths and designations (NASDAQ: WINT) Through three Phase 2 global studies, lead asset istaroxime has consi
Slide 4: Pipeline
Pipeline Lead Products |indicaton Istaroxime ‘Cardiogenic Shock Istaroxime ‘Acute Heart Failure OralSERCA2a Chronic Heart Failure, including Activators potentially HFPEF Treatment Resistant Rostafuroxin Hypertension - Genetically ‘Assocated KLASurfactant KU4 sufactat DrugDevce Tx Ce RERa Ga for RDS
Slide 5: Istaroxime: Cardiogenic Shock
Istaroxime Cardiogenic Shock Potential indication in active clinical development
Slide 6: Cardiogenic Shock
Cardiogenic Shock A severe presentation of heart failure characterized by very low blood pressure and hypoperfusion accompanied by high filling pressures of the heart and decreased urine output. Itis a treatment emergency. » Caused by severe impairment of cardiac function that results in diminished
Slide 7: Market Research: Early Cardiogenic Shock Treatment
Market Researc! Early Cardiogenic Shock Treatment Istaroxime Potential Opportunity to Address Significant Unmet Need * No satisfactory pharmacological intervention to reverse the conditions ~ Available therapies have unwanted side effects such as risk for arrhythmias, decreasing blood pressure, rena
Slide 8: Istaroxime — Novel First-in-Class Therapy
Istaroxime — Novel First-in-Class Therapy Novel intravenous agent designed to improve systolic contraction and diastolic relaxation of the heart Dual Mechanism of Action Stimulation of SERCA2a activity Inhibition of the soaium- . @ crimes acum reuptae potassium pump and effects on Istaroxime Teaulti
Slide 9: Rationale for Istaroxime in Cardiogenic Shock Came from AHF Phase 2 Trials
Rationale for Istaroxime in Cardiogenic Shock Came from AHF Phase 2 Trials Phase 2a and 2b data in AHF demonstrated istaroxime uniquely and significantly improved: vw Cardiac Function + increased stroke volume lowered cardiac filling pressures vo Dose Related Increases in Systolic Blood Pressure iv
Slide 10: Cardiogenic Shock Treatment: Regulatory Pathway
Cardiogenic Shock Treatment Istaroxime Potential Opportunity for Regulatory Pathway Potential for a relatively fast and less expensive developmental and regulatory pathway Oo | ‘Sponsors are potentially not required to show benefit other than an increase in blood pressure to support approval of drug
Slide 11: SEISMiC Early Cardiogenic Shock Study
SEISMIC Early Cardiogenic Shock Study Clinical strategy: Start development with patients in early cardiogenic shock caused by severe heart failure Ze 60 patients in early cardiogenic shock (SBP 75-0mmHg) with AHF + Study drug was infused for 24 hours ina 1:1 randomization to placebo or istaroxime. T
Slide 12: Primary Endpoint: Difference in SBP Profile
eta Difference in SBP Profile Systolic Blood Pressure AUC through 6 Hours - mITT Population 3" stanne zn lacebo EL Change from Baseline in SBP 0 os 1 is 2 28 3 40455 35) 6 8g Hours from Infusion Inititation WINDTREE
Slide 13: Secondary Results: Systolic BP Improvements Persisted over 24 Hours
& Secondary Results — Systolic BP Improvements Persisted over 24 Hours ‘Systolic Blood Pressure mITT Population € 2 Istaroxime © Placebo Change in SBP (mmHg) } t { p=0.025 for AUC 0 2 24 Hours from Infusion initiation
Slide 14: Cardiac Function Improvement
Cardiac Function Improvement Echocardiography demonstrated improvements in key systolic and diastolic cardiac function measures including: * Cardiac index significantly increased » Stroke volume index substantially increased (4 mL/m2) approaching statistical significance » Other echocardiographic me
Slide 15: Treatment was Associated with a Favorable Renal Profile
Treatment was Associated with a Favorable Renal Profile Renal function was not decreased in istaroxime treated patients , —____________ Estimated Glomerular Filtration Rate ‘miTT Population eo Istaroxime ‘change trom Baseline in GFR (miminit.73m°) 5) =e Pracedo 2 ° 2 as 36 * cy 2 ee 8 ours from infu
Slide 16: Comparison of Doses
& Comparison of Doses 1.0 yg/kg/min Produced a Favorable Effect on SBP 1.0 ugikg/min dosing was associated with: * Early, rapid SBP increase and improvement in more echocardiographic assessments of cardiac function * More favorable adverse event, serious adverse event and clinical event profile 210
Slide 17: SEISMiC Results Summary
SEISMiC Results Summary SEISMIC was a positive study in early cardiogenic shock patients v Systolic blood pressure significantly increased within the first 6 hours of initiating the infusion (p=0.017) and the increase was maintained throughout the 24-hour infusion (p=0.025) » SBP increases were rapi
Slide 18: Cardiogenic Shock Development Strategy
Cardiogenic Shock Development Strategy se fd WINDTREE SEISMIC Extension Study = Extended and titrated dosing for optimization SEISMIC * Additional characterization Phase 3* Sf SENEA a eet + Execute EOP2 meeting Study with these 3 studies augmented by AHF * Proof of Concept SS) safety data base, etc.
Slide 19: Plan for Dose Optimization — Extension Study
Plan for Dose Optimization — Extension Study Following the positive results in the early cardiogenic shock study, an extension study is planned to support ‘ongoing development in early cardiogenic shock and acute heart failure Study objectives: v Advance the characterization of the physiology associ
Slide 20: Cardiogenic Shock Opportunity
Cardiogenic Shock Opportunity ITENDED TARGET THERAPEUTIC PROFILE For patients in cardiogenicshock due to heart failure, istaroxime will be a unique, first-in-class dual action agent anda treatment for cardiogenicshock that rapidly and significantly improves blood pressure and cardiac output performa
Slide 21: Istaroxime: Acute Heart Failure
Istaroxime Dual Mechanism SERCA2a Activator Acute Heart
Slide 22: Heart Failure — Large, Growing Market But Underserved
Heart Failure —- Large, Growing Market But Underserved The prevalence and mortality of heart failure is high and increasing #1 cause of U.S. Annual Admissions Patients ~ hospitalization ~1.3M us 7Mus,, Wy in patients ~1. + > 65 years old 1.5M cv. 25M F worawide ~7% ByErsisB Gf o &) In-patient mortal
Slide 23: Acute Heart Failure — Significant Unmet Clinical Need
Acute Heart Failure — Significant Unmet Clinical Need Patient Management Goals Current Treatment Option: » Clinical objectives for AHF » Current approaches to acutely improve cardiac patient management include: function are associated with unwanted effects: ~ Relieve pulmonary ~ Heart rhythm disturb
Slide 24: Istaroxime AHF Phase 2a & 2b Studies
Istaroxime AHF Phase 2a & 2b Studies 3) + Primary: PCWP significantly improved Phase + Stroke Vol & SBP — significantincrease 2a n=120 Dosing Ghour —._ Heart Rate (HR) - lowered ADHE Patients 0.5, 1, 1.5 yokomn Infusion Phase n=120 Dosing= 24 hour 2b ADHF Patients 9.5, 1.0 ugkaimin Infusion (@yspnea
Slide 25: Primary Endpoint Achieved
Primary Endpoint Achieved Significant Changes in E/e' Ratio’ and Stroke Volume Istaroxime 0.5 yig/kg/min vs. placebo Istaroxime 1.0 yg/kg/min vs. placebo gx Ele’ 23 Bas “0 Infusion period * pvalue = 0.029 pl infusion period “p-values 0.034 Cassie —hans tout ar Se) Seay ee 9 Plaeos-conett — esitzoine
Slide 26: Systolic Blood Pressure Increased During Treatment and Renal Function Tended to Improve
Systolic Blood Pressure Increased During Treatment and Renal Function Tended to Improve Istaroxime 0.5 yig/kg/min vs. placebo Istaroxime 1.0 yg/kg/min vs. placebo 3? 1 pyalue=0.011 > Rt * paues £0005 Pressure (sBP) ae 4 i: | B ‘ inusionperoa Trusion period “mens en -0= Placedo-Conot2 — <=@eistaronim
Slide 27: Heart Rate Decreased and No Increases in Cardiac Troponins
Heart Rate Decreased and No Increases in Cardiac Troponins se fd WINDTREE ane ata pm) Istaroxime 0.5 ygikg/min vs. placebo Infusion period Cardiac Tat (Myocardial Damage) Istaroxime 1.0 g/kg/min vs. placebo *pwaue=0.011 ~"pvalues £0 068
Slide 28: Favorable Profile Observed with 24-hour Holter Monitoring
Favorable Profile Observed with 24-hour Holter Monitoring Clinically Significant Arrhythmias a L. L ta ‘Basen 1 Usa) Ow? Basen Day onsen) a2 sPacrbo-Conot—— mitaoxine Sugg sPctbo-Coon? istzuine 10K . Ventricular Tachycardia cams 700% — av 1 | an _ 00% 00% Basaine Oa Vso) a? oO ie Om ndson Da? & aPuc
Slide 29: Istaroxime — Acute Heart Failure Phase 3 Program
NIE Istaroxime — Acute Heart Failure Objective: Evaluate potential Phase 3 AHF program based on data from our cardiogenic shock program Potential Phase 3 AHF Program Augment our data from the positive phase 2a and phase 2b AHF studies = with the efficacy, safety and dosing and characterization learn
Slide 30: Next Generation, Oral SERCA2a Activators Acute and Chronic Heart Failure Platform
Next Generation, Oral SERCA2a Activators Acute and Chronic Heart Failure Platform The Company also has pre-clinical programs on product candidates including: Selective SERCA2Za Dual Mechanism, (SERCA2a & Na+/K+) Activators Compounds + Oral & i.v. therapies for chronic “Next generation istaroxime” as
Slide 31: Summary
Summary vi" Istaroxime has produced positive, differentiating data in three Phase 2 studies for two separate and complementary indications. These markets have significant unmet needs, and no known other late-stage programs in development to address the acute decompensated patient The data is consist
Slide 32: Rostafuroxin: Resistant Hypertension
Specifically displaces ouabain binding from the high affinity Na+— K+ATPase isoform present in the caveolae, antagonizing all the functional effects of ouabain SZ winotRee oy esistant Hypertension (RHTN Rostafuroxin There have been seven clinical studies of rostafuroxin in treatment naive hypertensi
Slide 33: High Potential Value in Treatment Resistant Hypertension Market
High Potential Value in Treatment Resistant Hypertension Market Large Market with Significant Unmet Need Significant Value Potential i i * Two biotech companies have * Treatment resistant hypertension ai An estimated 10% to 20% of demonstrated the significant value the i F market is placing on RHTN
Slide 34: Active Engagement in Out-License and Partnership Opportunities
Active Engagement in Out-License and Partnership Opportunities v AEROSURF / KL4 Platform — Exclusive global license to Lee’s Pharm (SEHK:950) and Zhaoke. Potential proceeds: ‘© Up to $78.9 million in potential milestone payments Gopal Bedional © Low double-digit % royalties Licensi © WINT no longer
Slide 35: Financial Summary & Capitalization
Financial Summary & Capitalization Investme Capital Efficiency to Prog Common Equivalents Securities | 35 of February 28, 2023 Significantly reduced company expenses and cash burn via out- licensing KL4 platform, focused resources on lead priority program Common Stock 904,459 = Total Company Burn /
Slide 36: Strategy for Value Generation
Strategy for Value Generation Communicate Our Milestones Transactions WA Optimization vv Secure focused BD Bring in new, well- transactions for deal revenue sulted development and non-dilutive financial supportof clinical opportunities and development transactions Progress heart failure platformto a
Slide 37: Slide 37
Windtree Therapeutics — Investor Presentation (April 2023) on 6ix